A Phase 2 interventional study of Placebo and ALN-AGT01 in Hypertension, sponsored by Alnylam Pharmaceuticals. Completed at 75 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by Alnylam Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.
Among the 2,031 studies in Hypertension with a site in United States, this one is the 406th largest by enrollment of the 1,779 interventional ones that give a count, is one of 96 that started in 2021, is one of 170 in phase 2, and was the 1,489th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 16–56 · Women only
The University of Texas at Arlington · Sites in United States
Ages 26–49
CRISPR Therapeutics AG · Sites in United States, Australia, United Kingdom
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,031 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 147 · Phase 2 216 · Phase 3 214 · Phase 4 188
First in 1973; this study’s year is marked. 96 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 394 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 100 across the 1,779 interventional studies, 200 across the 238 observational. Of the 1,514 that completed or were terminated, 578 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
461 of 2,031 have an industry lead sponsor. The 10 most frequent:
Alnylam Pharmaceuticals is the lead sponsor of 84 studies on the registry; 18 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 15 (83%) have results posted.
Alnylam Pharmaceuticals has 7 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
143 of the studies in Hypertension with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT04971720Phase 3University of Alabama at BirminghamPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis | 2027-01-01 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
Add all 143 to your calendar (.ics) → With an account.
Among the 2,031 studies in Hypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.
Participants will receive ALN-AGT01 or placebo for the first 6 months of the 12-month double-blind (DB) treatment period. Participants randomized to placebo will be re-randomized at Month 6 to 1 of the 4 initial ALN-AGT01 regimens until the end of the 12-month DB treatment period. Participants randomized to ALN-AGT01 regimens will remain on their originally assigned regimens through remainder of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received zilebesiran matching placebo, subcutaneous (SC) injection, once every 3 months (Q3M), with re-randomization at Month 6 to 1 of the initial 4 zilebesiran regimens. Participants will continue their respective zilebesiran regimen up to Month 12 in the DB period and up to 24 additional months in the DB Extension period. Upon implementation of Amendment 6, the DB Extension period was closed.
Drug: Placebo · Drug: ALN-AGT01
Participants receive zilebesiran, 150 mg, SC injection, Q6M, during the 12-month DB period. Participants will continue receiving the same zilebesiran regimen for up to 24 additional months in the DB Extension period. Participants in this arm will receive a placebo during those dosing visits when they do not receive zilebesiran to maintain the blind. Upon implementation of Amendment 6, the DB Extension period was closed.
Drug: Placebo · Drug: ALN-AGT01
Participants receive zilebesiran, 300 mg, SC injection, Q6M, during the 12-month DB period. Participants will continue receiving the same zilebesiran regimen for up to 24 additional months in the DB Extension period. Participants in this arm will receive a placebo during those dosing visits when they do not receive zilebesiran to maintain the blind. Upon implementation of Amendment 6, the DB Extension period was closed.
Drug: Placebo · Drug: ALN-AGT01
Participants receive zilebesiran, 300 mg, SC injection, Q3M, during the 12-month DB period. Participants continue receiving the same zilebesiran regimen for up to 24 additional months in the DB Extension period. Upon implementation of Amendment 6, the DB Extension period was closed.
Drug: ALN-AGT01
Participants receive zilebesiran, 600 mg, SC injection, Q6M, during the 12-month DB period. Participants will continue receiving the same zilebesiran regimen for up to 24 additional months in the DB Extension period. Participants in this arm will receive a placebo during those dosing visits when they do not receive zilebesiran to maintain the blind. Upon implementation of Amendment 6, the DB Extension period was closed.
Drug: Placebo · Drug: ALN-AGT01
Placebo administered by SC injection
ALN-AGT01 administered by SC injection
Also known as: Zilebesiran
Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM
24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of BP by each hour of the day. The 24-hour mean was the average of the hourly means. Least squares (LS) mean and standard error (SE) were calculated using a mixed model repeated measures (MMRM) approach.
Time frame: Baseline and Month 3
Change From Baseline at Month 3 in Mean Sitting Office SBP
The mean office BP in the sitting position was used for the analysis. Office BP in the sitting position was collected with a set of 4 replicates. The average of the last 3 replicates was calculated and used for analysis. LS mean and SE were calculated using a MMRM approach.
Time frame: Baseline and Month 3
Change From Baseline at Month 6 in 24-hour Mean SBP Assessed by ABPM
24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of blood pressure (BP) by each hour of the day. The 24-hour mean was the average of the hourly means. LS mean and SE were calculated using a MMRM approach.
Time frame: Baseline and Month 6
Change From Baseline at Month 6 in Mean Sitting Office SBP
The mean office BP in the sitting position was used for the analysis. Office BP in the sitting position was collected with a set of 4 replicates. The average of the last 3 replicates was calculated and used for analysis. LS mean and SE were calculated using a MMRM approach.
Time frame: Baseline and Month 6
Percentage of Participants With 24-hour Mean SBP Assessed by ABPM <130 mmHg and/or Reduction of ≥20 mmHg From Baseline Without Additional Antihypertensive Medications at Month 6
24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of blood pressure (BP) by each hour of the day. The 24-hour mean was the average of the hourly means.
Time frame: Month 6
Change From Baseline at Month 3 in 24-hour Mean DBP Assessed by ABPM
24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of blood pressure (BP) by each hour of the day. The 24-hour mean was the average of the hourly means. LS mean and SE were calculated using a MMRM approach.
Time frame: Baseline and Month 3
Change From Baseline at Month 6 in 24-hour Mean DBP Assessed by ABPM
24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of blood pressure (BP) by each hour of the day. The 24-hour mean was the average of the hourly means. LS mean and SE were calculated using a MMRM approach
Time frame: Baseline and Month 6
Change From Baseline at Month 3 in Mean Sitting Office DBP
The mean office BP in the sitting position was used for the analysis. Office BP in the sitting position was collected with a set of 4 replicates. The average of the last 3 replicates was calculated and used for analysis. LS mean and SE were calculated using a MMRM approach.
Time frame: Baseline and Month 3
Time Adjusted Change From Baseline Through Month 3 in Mean Sitting Office SBP and DBP
Time adjusted change from baseline in mean sitting office SBP and DBP was the area under the curve (AUC) between Month 1 and 3 visits divided by the duration of time period.
Time frame: Baseline and Month 3
Change From Baseline at Month 6 in Mean Sitting Office DBP
The mean office BP in the sitting position was used for the analysis. Office BP in the sitting position was collected with a set of 4 replicates. The average of the last 3 replicates was calculated and used for analysis. LS mean and SE were calculated using a MMRM approach.
Time frame: Baseline and Month 6
Time Adjusted Change From Baseline Through Month 6 in 24-hour Mean SBP and DBP Assessed by ABPM
Time adjusted change from baseline through Month 6 in 24-hour mean SBP and DBP was determined as the AUC between Month 1 and 6 visits divided by the duration of the time period.
Time frame: Baseline and Month 6
Time Adjusted Change From Baseline Through Month 6 in Mean Sitting Office SBP and DBP
Time adjusted change is the AUC between Month 1 and 6 visits divided by the duration of time period.
Time frame: Baseline and Month 6
Change From Baseline in Daytime/Nighttime Mean SBP and DBP Assessed by ABPM at Each Visit
ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, and 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). Baseline was defined as the last assessment prior to receiving the first dose of study drug. LS mean and SE were calculated using a MMRM approach.
Time frame: Baseline, and Months 1, 3 and 6
Percentage Change From Baseline in Serum Angiotensinogen (AGT) Through Month 6
Time frame: Baseline, Week 2 and Months 1, 2, 3, 4, 5 and 6
Total of 86 clinical sites across North America \& 25 sites in Europe enrolled 394 participants. 16 participants from Ukraine were unable to continue participation due to geopolitical instability. Due to challenges in data collection \& cleaning, these participants were excluded from all analysis sets. Hence, results are presented for 378 randomized participants. Study has 2 periods: 6-Month Placebo-controlled Double-blind (DB) Period \& Post-6-Month DB Period \[DB (Months 6 to 12)+DB Extension\].
| Milestone | Placebo | Zilebesiran 150 Milligrams (mg) Once Every 6 Months (Q6M) | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M | Placebo/Zilebesiran 150 mg Q6M | Placebo/Zilebesiran 300 mg Q6M | Placebo/Zilebesiran 300 mg Q3M | Placebo/Zilebesiran 600 mg Q6M | Zilebesiran/Zilebesiran 150 mg Q6M | Zilebesiran/Zilebesiran 300 mg Q6M | Zilebesiran/Zilebesiran 300 mg Q3M | Zilebesiran/Zilebesiran 600 mg Q6M |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 76 | 78 | 73 | 75 | 76 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 70 | 70 | 70 | 70 | 71 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 6 | 8 | 3 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Subject stopped participation in the study | 5 | 5 | 1 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Reason unknown | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Zilebesiran 150 Milligrams (mg) Once Every 6 Months (Q6M) | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M | Placebo/Zilebesiran 150 mg Q6M | Placebo/Zilebesiran 300 mg Q6M | Placebo/Zilebesiran 300 mg Q3M | Placebo/Zilebesiran 600 mg Q6M | Zilebesiran/Zilebesiran 150 mg Q6M | Zilebesiran/Zilebesiran 300 mg Q6M | Zilebesiran/Zilebesiran 300 mg Q3M | Zilebesiran/Zilebesiran 600 mg Q6M |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 17 | 17 | 16 | 18 | 69 | 67 | 66 | 65 |
| Completed month 12 visit | 0 | 0 | 0 | 0 | 0 | 13 | 16 | 16 | 18 | 65 | 62 | 65 | 61 |
| Completed | 0 | 0 | 0 | 0 | 0 | 12 | 15 | 15 | 18 | 60 | 57 | 59 | 58 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 5 | 2 | 1 | 0 | 9 | 10 | 7 | 7 |
| Withdrew: Participant stopped participation in the study | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 2 | 7 | 5 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 3 | 1 | 1 | 4 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of BP by each hour of the day. The 24-hour mean was the average of the hourly means. Least squares (LS) mean and standard error (SE) were calculated using a mixed model repeated measures (MMRM) approach.
| millimeters of mercury (mmHg) | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M and Q3M | Zilebesiran 600 mg Q6M |
|---|---|---|---|---|
| Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM | 6.8 ± 1.58 | -7.3 ± 1.49 | -10.0 ± 1.05 | -8.9 ± 1.52 |
The mean office BP in the sitting position was used for the analysis. Office BP in the sitting position was collected with a set of 4 replicates. The average of the last 3 replicates was calculated and used for analysis. LS mean and SE were calculated using a MMRM approach.
| mmHg | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M and Q3M | Zilebesiran 600 mg Q6M |
|---|---|---|---|---|
| Change From Baseline at Month 3 in Mean Sitting Office SBP | -0.1 ± 1.57 | -9.7 ± 1.49 | -12.1 ± 1.06 | -9.2 ± 1.52 |
24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of blood pressure (BP) by each hour of the day. The 24-hour mean was the average of the hourly means. LS mean and SE were calculated using a MMRM approach.
| mmHg | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M |
|---|---|---|---|---|---|
| Change From Baseline at Month 6 in 24-hour Mean SBP Assessed by ABPM | 4.6 ± 1.73 | -6.5 ± 1.63 | -9.9 ± 1.58 | -9.5 ± 1.65 | -9.6 ± 1.62 |
The mean office BP in the sitting position was used for the analysis. Office BP in the sitting position was collected with a set of 4 replicates. The average of the last 3 replicates was calculated and used for analysis. LS mean and SE were calculated using a MMRM approach.
| mmHg | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M |
|---|---|---|---|---|---|
| Change From Baseline at Month 6 in Mean Sitting Office SBP | -0.6 ± 1.80 | -8.2 ± 1.70 | -11.1 ± 1.67 | -12.8 ± 1.80 | -10.8 ± 1.73 |
24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of blood pressure (BP) by each hour of the day. The 24-hour mean was the average of the hourly means.
| percentage of participants | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M |
|---|---|---|---|---|---|
| Percentage of Participants With 24-hour Mean SBP Assessed by ABPM <130 mmHg and/or Reduction of ≥20 mmHg From Baseline Without Additional Antihypertensive Medications at Month 6 | 6.7 | 30.8 | 50.7 | 38.7 | 47.4 |
24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of blood pressure (BP) by each hour of the day. The 24-hour mean was the average of the hourly means. LS mean and SE were calculated using a MMRM approach.
| mmHg | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M and Q3M | Zilebesiran 600 mg Q6M |
|---|---|---|---|---|
| Change From Baseline at Month 3 in 24-hour Mean DBP Assessed by ABPM | 3.5 ± 0.87 | -4.5 ± 0.82 | -5.7 ± 0.58 | -5.8 ± 0.84 |
24-hour ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were≥11, 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). To summarize the 24-hour ABPM, the hourly adjusted mean was calculated. Hourly mean was the average of blood pressure (BP) by each hour of the day. The 24-hour mean was the average of the hourly means. LS mean and SE were calculated using a MMRM approach
| mmHg | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M |
|---|---|---|---|---|---|
| Change From Baseline at Month 6 in 24-hour Mean DBP Assessed by ABPM | 2.2 ± 0.97 | -4.8 ± 0.91 | -6.1 ± 0.89 | -6.3 ± 0.93 | -6.3 ± 0.91 |
The mean office BP in the sitting position was used for the analysis. Office BP in the sitting position was collected with a set of 4 replicates. The average of the last 3 replicates was calculated and used for analysis. LS mean and SE were calculated using a MMRM approach.
| mmHg | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M and Q3M | Zilebesiran 600 mg Q6M |
|---|---|---|---|---|
| Change From Baseline at Month 3 in Mean Sitting Office DBP | -0.6 ± 1.00 | -5.3 ± 0.94 | -7.0 ± 0.67 | -5.4 ± 0.97 |
Time adjusted change from baseline in mean sitting office SBP and DBP was the area under the curve (AUC) between Month 1 and 3 visits divided by the duration of time period.
| mmHg | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M and Q3M | Zilebesiran 600 mg Q6M |
|---|---|---|---|---|
| Office SBP | -0.6 ± 1.29 | -9.1 ± 1.24 | -10.9 ± 0.89 | -10.1 ± 1.26 |
| Office DBP | -0.0 ± 0.80 | -4.8 ± 0.77 | -6.5 ± 0.55 | -6.0 ± 0.78 |
The mean office BP in the sitting position was used for the analysis. Office BP in the sitting position was collected with a set of 4 replicates. The average of the last 3 replicates was calculated and used for analysis. LS mean and SE were calculated using a MMRM approach.
| mmHg | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M |
|---|---|---|---|---|---|
| Change From Baseline at Month 6 in Mean Sitting Office DBP | -1.2 ± 1.20 | -4.1 ± 1.13 | -6.8 ± 1.12 | -8.2 ± 1.20 | -5.0 ± 1.16 |
Time adjusted change from baseline through Month 6 in 24-hour mean SBP and DBP was determined as the AUC between Month 1 and 6 visits divided by the duration of the time period.
| mmHg | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M |
|---|---|---|---|---|---|
| 24-hour Mean SBP | 5.8 ± 1.26 | -6.3 ± 1.20 | -9.2 ± 1.20 | -9.6 ± 1.22 | -9.1 ± 1.22 |
| 24-hour Mean DBP | 3.1 ± 0.72 | -4.2 ± 0.69 | -5.5 ± 0.69 | -5.8 ± 0.70 | -5.9 ± 0.70 |
Time adjusted change is the AUC between Month 1 and 6 visits divided by the duration of time period.
| mmHg | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M |
|---|---|---|---|---|---|
| Office SBP | -0.5 ± 1.25 | -9.0 ± 1.20 | -12.1 ± 1.21 | -11.0 ± 1.24 | -10.0 ± 1.22 |
| Office DBP | -0.6 ± 0.80 | -4.7 ± 0.76 | -7.2 ± 0.77 | -6.7 ± 0.79 | -5.5 ± 0.78 |
ABPM was programmed to take readings every 20 minutes during the day (6 am to 9:59 pm) and every 30 minutes during the night (10 pm to 5:59 am). An ABPM was considered adequate if: 1. the number of successful daytime readings were ≥33, 2. the number of successful nighttime readings were ≥11, and 3. no more than 3 hours are not represented (i.e., 3 sections of 60 minutes where 0 valid readings were obtained). Baseline was defined as the last assessment prior to receiving the first dose of study drug. LS mean and SE were calculated using a MMRM approach.
| mmHg | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M |
|---|---|---|---|---|---|
| Change in Daytime Mean SBP at Month 1 | 4.3 ± 1.50 | -3.6 ± 1.45 | -6.4 ± 1.51 | -9.6 ± 1.46 | -9.1 ± 1.48 |
| Change in Daytime Mean SBP at Month 3 | 6.7 ± 1.62 | -7.6 ± 1.53 | -10.7 ± 1.52 | -9.8 ± 1.54 | -8.9 ± 1.56 |
| Change in Daytime Mean SBP at Month 6 | 4.5 ± 1.83 | -6.9 ± 1.72 | -10.4 ± 1.66 | -9.3 ± 1.74 | -8.8 ± 1.71 |
| Change in Nighttime Mean SBP at Month 1 | 4.7 ± 1.64 | -3.4 ± 1.59 | -5.1 ± 1.64 | -9.5 ± 1.60 | -8.0 ± 1.62 |
| Change in Nighttime Mean SBP at Month 3 | 7.0 ± 1.85 | -6.4 ± 1.76 | -8.2 ± 1.74 | -9.7 ± 1.77 | -8.5 ± 1.79 |
| Change in Nighttime Mean SBP at Month 6 | 4.7 ± 1.86 | -5.8 ± 1.75 | -8.9 ± 1.69 | -10.2 ± 1.78 | -11.1 ± 1.74 |
| Change in Daytime Mean DBP at Month 1 | 2.9 ± 0.91 | -2.7 ± 0.88 | -4.0 ± 0.91 | -5.9 ± 0.89 | -5.8 ± 0.89 |
| Change in Daytime Mean DBP at Month 3 | 3.5 ± 0.94 | -4.8 ± 0.89 | -6.1 ± 0.88 | -5.7 ± 0.90 | -5.6 ± 0.90 |
| Change in Daytime Mean DBP at Month 6 | 2.1 ± 1.07 | -4.8 ± 1.01 | -6.2 ± 0.98 | -6.1 ± 1.02 | -5.7 ± 1.00 |
| Change in Nighttime Mean DBP at Month 1 | 3.2 ± 1.01 | -2.4 ± 0.98 | -3.5 ± 1.02 | -5.9 ± 0.99 | -5.4 ± 1.00 |
| Change in Nighttime Mean DBP at Month 3 | 3.7 ± 1.08 | -3.6 ± 1.02 | -5.1 ± 1.01 | -4.8 ± 1.03 | -5.8 ± 1.04 |
| Change in Nighttime Mean DBP at Month 6 | 2.2 ± 1.09 | -4.3 ± 1.03 | -5.9 ± 1.00 | -6.7 ± 1.05 | -7.6 ± 1.03 |
| percent change | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M |
|---|---|---|---|---|---|
| Percent Change from Baseline at Week 2 | -0.05 ± 23.99 | -88.34 ± 9.96 | -92.68 ± 4.40 | -92.77 ± 4.03 | -94.49 ± 5.52 |
| Percent Change from Baseline at Month 1 | 1.61 ± 22.96 | -94.48 ± 9.04 | -97.38 ± 1.72 | -97.20 ± 2.30 | -98.22 ± 2.69 |
| Percent Change from Baseline at Month 2 | -2.06 ± 21.87 | -94.47 ± 12.38 | -97.74 ± 2.04 | -97.64 ± 2.15 | -98.70 ± 0.74 |
| Percent Change from Baseline at Month 3 | -2.19 ± 22.86 | -93.31 ± 9.94 | -97.26 ± 2.78 | -97.00 ± 2.61 | -98.25 ± 1.60 |
| Percent Change from Baseline at Month 4 | 1.39 ± 26.06 | -91.89 ± 11.61 | -95.94 ± 5.23 | -98.38 ± 1.08 | -97.98 ± 1.74 |
| Percent Change from Baseline at Month 5 | -2.27 ± 21.18 | -90.10 ± 12.48 | -94.85 ± 6.58 | -98.23 ± 1.13 | -97.38 ± 2.41 |
| Percent Change from Baseline at Month 6 | -4.97 ± 24.90 | -87.84 ± 13.82 | -93.13 ± 8.29 | -97.71 ± 1.91 | -96.41 ± 4.04 |
Collected over 6-Month Placebo-controlled DB Period: Day1 up to Month 6; Post-6-Month DB Period: Pbo/Zil arms: From first zilebesiran dose (Month 6) up to Month 36; Zil/ Zil: From first zilebesiran dose (Day 1) up to Month 36 Placebo-controlled DB: Safety Analysis Set=all participants who received any amount of study drug, grouped per treatment received. As planned, AEs were reported for Zilebesiran Treatment Period using All Zilebesiran Treated Set showing data by treatment sequence (Pbo/Zil & Zil/Zil).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/75 (0%) | 5/75 (6.7%) | 18/75 (24%) |
| Zilebesiran 150 mg Q6M | 0/78 (0%) | 0/78 (0%) | 21/78 (26.9%) |
| Zilebesiran 300 mg Q6M | 0/73 (0%) | 1/73 (1.4%) | 24/73 (32.9%) |
| Zilebesiran 300 mg Q3M | 1/75 (1.3%) | 4/75 (5.3%) | 23/75 (30.7%) |
| Zilebesiran 600 mg Q6M | 0/76 (0%) | 6/76 (7.9%) | 20/76 (26.3%) |
| Placebo/Zilebesiran 150 mg Q6M | 0/16 (0%) | 1/16 (6.3%) | 9/16 (56.3%) |
| Placebo/Zilebesiran 300 mg Q6M | 0/16 (0%) | 0/16 (0%) | 12/16 (75%) |
| Placebo/Zilebesiran 300 mg Q3M | 0/16 (0%) | 1/16 (6.3%) | 9/16 (56.3%) |
| Placebo/Zilebesiran 600 mg Q6M | 0/18 (0%) | 0/18 (0%) | 8/18 (44.4%) |
| Zilebesiran/Zilebesiran 150 mg Q6M | 1/78 (1.3%) | 5/78 (6.4%) | 53/78 (67.9%) |
| Zilebesiran/Zilebesiran 300 mg Q6M | 0/73 (0%) | 5/73 (6.8%) | 47/73 (64.4%) |
| Zilebesiran/Zilebesiran 300 mg Q3M | 1/75 (1.3%) | 7/75 (9.3%) | 49/75 (65.3%) |
| Zilebesiran/ Zilebesiran 600 mg Q6M | 0/76 (0%) | 9/76 (11.8%) | 49/76 (64.5%) |
| Event | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M | Placebo/Zilebesiran 150 mg Q6M | Placebo/Zilebesiran 300 mg Q6M | Placebo/Zilebesiran 300 mg Q3M | Placebo/Zilebesiran 600 mg Q6M | Zilebesiran/Zilebesiran 150 mg Q6M | Zilebesiran/Zilebesiran 300 mg Q6M | Zilebesiran/Zilebesiran 300 mg Q3M | Zilebesiran/ Zilebesiran 600 mg Q6M |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UrosepsisInfections and infestations | 0/75 | 0/78 | 0/73 | 0/75 | 0/76 | 0/16 | 0/16 | 1/16 | 0/18 | 0/78 | 0/73 | 0/75 | 1/76 |
| Alanine aminotransferase increasedInvestigations | 0/75 | 0/78 | 0/73 | 0/75 | 0/76 | 1/16 | 0/16 | 0/16 | 0/18 | 0/78 | 0/73 | 0/75 | 0/76 |
| Aspartate aminotransferase increasedInvestigations | 0/75 | 0/78 | 0/73 | 0/75 | 0/76 | 1/16 | 0/16 | 0/16 | 0/18 | 0/78 | 0/73 | 0/75 | 0/76 |
| Acute kidney injuryRenal and urinary disorders | 0/75 | 0/78 | 0/73 | 0/75 | 0/76 | 0/16 | 0/16 | 1/16 | 0/18 | 1/78 | 0/73 | 0/75 | 0/76 |
| Duodenal ulcer haemorrhageGastrointestinal disorders | 0/75 | 0/78 | 1/73 | 0/75 | 0/76 | 0/16 | 0/16 | 0/16 | 0/18 | 0/78 | 1/73 | 0/75 | 0/76 |
| FallInjury, poisoning and procedural complications | 0/75 | 0/78 | 0/73 | 0/75 | 0/76 | 0/16 | 0/16 | 0/16 | 0/18 | 1/78 | 1/73 | 0/75 | 0/76 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/75 | 0/78 | 0/73 | 0/75 | 0/76 | 0/16 | 0/16 | 0/16 | 0/18 | 0/78 | 1/73 | 0/75 | 0/76 |
| Paraganglion neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/75 | 0/78 | 0/73 | 0/75 | 0/76 | 0/16 | 0/16 | 0/16 | 0/18 | 0/78 | 1/73 | 0/75 | 0/76 |
| SyncopeNervous system disorders | 0/75 | 0/78 | 0/73 | 0/75 | 0/76 | 0/16 | 0/16 | 0/16 | 0/18 | 1/78 | 1/73 | 0/75 | 0/76 |
| Acute coronary syndromeCardiac disorders | 0/75 | 0/78 | 0/73 | 1/75 | 0/76 | 0/16 | 0/16 | 0/16 | 0/18 | 0/78 | 0/73 | 1/75 | 0/76 |
| Event | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M | Placebo/Zilebesiran 150 mg Q6M | Placebo/Zilebesiran 300 mg Q6M | Placebo/Zilebesiran 300 mg Q3M | Placebo/Zilebesiran 600 mg Q6M | Zilebesiran/Zilebesiran 150 mg Q6M | Zilebesiran/Zilebesiran 300 mg Q6M | Zilebesiran/Zilebesiran 300 mg Q3M | Zilebesiran/ Zilebesiran 600 mg Q6M |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 0/75 | 3/78 | 4/73 | 8/75 | 4/76 | 0/16 | 3/16 | 1/16 | 1/18 | 5/78 | 8/73 | 13/75 | 9/76 |
| Urinary tract infectionInfections and infestations | 0/75 | 0/78 | 0/73 | 0/75 | 0/76 | 1/16 | 0/16 | 3/16 | 1/18 | 3/78 | 5/73 | 9/75 | 3/76 |
| DiarrhoeaGastrointestinal disorders | 0/75 | 0/78 | 0/73 | 0/75 | 0/76 | 2/16 | 0/16 | 0/16 | 0/18 | 1/78 | 2/73 | 3/75 | 1/76 |
| Upper respiratory tract infectionInfections and infestations | 1/75 | 3/78 | 4/73 | 2/75 | 1/76 | 2/16 | 0/16 | 1/16 | 1/18 | 6/78 | 5/73 | 6/75 | 4/76 |
| Back painMusculoskeletal and connective tissue disorders | 0/75 | 0/78 | 0/73 | 0/75 | 0/76 | 0/16 | 2/16 | 0/16 | 0/18 | 2/78 | 3/73 | 3/75 | 2/76 |
| HypotensionVascular disorders | 0/75 | 0/78 | 0/73 | 0/75 | 0/76 | 0/16 | 0/16 | 2/16 | 0/18 | 2/78 | 1/73 | 2/75 | 2/76 |
| Coronavirus Disease of 2019 (COVID-19)Infections and infestations | 3/75 | 3/78 | 6/73 | 6/75 | 4/76 | 0/16 | 1/16 | 0/16 | 0/18 | 7/78 | 7/73 | 9/75 | 8/76 |
| HypertensionVascular disorders | 5/75 | 4/78 | 0/73 | 3/75 | 5/76 | 1/16 | 0/16 | 1/16 | 0/18 | 9/78 | 3/73 | 4/75 | 9/76 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/75 | 2/78 | 4/73 | 2/75 | 0/76 | 0/16 | 0/16 | 0/16 | 2/18 | 3/78 | 6/73 | 4/75 | 0/76 |
| DizzinessNervous system disorders | 4/75 | 2/78 | 2/73 | 3/75 | 3/76 | 0/16 | 0/16 | 0/16 | 1/18 | 3/78 | 3/73 | 4/75 | 8/76 |
The Full Analysis Set included all randomized participants who received any amount of the study drug.
| Age, Continuous(years) | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M | Total |
|---|---|---|---|---|---|---|
| Mean | 56.8 ± 11.2 | 55.5 ± 10.6 | 56.4 ± 10.3 | 57.7 ± 10.6 | 57.4 ± 10.2 | 56.8 ± 10.6 |
| Sex: Female, Male(Participants) | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M | Total |
|---|---|---|---|---|---|---|
| Female | 38 | 39 | 29 | 30 | 31 | 167 |
| Male | 37 | 39 | 44 | 45 | 45 | 210 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 19 | 16 | 10 | 20 | 74 |
| Not Hispanic or Latino | 66 | 59 | 57 | 65 | 56 | 303 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 1 |
| Asian | 5 | 4 | 2 | 7 | 5 | 23 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 1 |
| Black or African American | 18 | 20 | 17 | 19 | 19 | 93 |
| White | 52 | 53 | 54 | 48 | 52 | 259 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| 24-hour Mean Systolic Blood Pressure (SBP) Assessed by Ambulatory Blood Pressure Monitoring (ABPM)(millimeter of mercury (mmHg)) | Placebo | Zilebesiran 150 mg Q6M | Zilebesiran 300 mg Q6M | Zilebesiran 300 mg Q3M | Zilebesiran 600 mg Q6M | Total |
|---|---|---|---|---|---|---|
| Mean | 141.1 ± 7.9 | 140.6 ± 8.5 | 142.5 ± 8.8 | 141.6 ± 7.7 | 143.1 ± 9.0 | 141.8 ± 8.4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Requests for access to data can be submitted via the website www.vivli.org.
Ran from Jul 2021 to primary completion in Apr 2023, 20 months.
Results were first posted in Dec 2024, 1 year 8 months after primary completion. A results delay was requested in Feb 2024.
Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 20 months is above that.
Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zilebesiran